Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Tesamorelin produced an average 15.2% reduction in visceral adipose tissue at 26 weeks in its pivotal Phase 3 trial, versus a 5.0% increase in placebo-treated participants (Falutz et al., NEJM 2007
it modulates the expression of over 4,000 human genes, including those responsible for inflammation control, DNA repair, collagen and elastin synthesis, antioxidant defense, and stem cell activity
Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity
For personalised health advice, please consult a qualified healthcare professional.
An experienced clinician can provide useful assessments, including potential risks
US$ 28.51
US$ 29.39
US$ 24.50
US$ 28.79
US$ 21.97
US$ 21.26
